SPI Infoamtion

Table of Contents

Executive Summary

The macroeconomic environment in China
The Chinese healthcare system
Chinese hospital market analysis
Key players in the Chinese hospital pharmaceutical market

Chapter 1 Scope and methodology

Scope
Methodology
IMS caveat

Chapter 2 The macroeconomic environment in China

Summary
Introduction
Population profile
Disease burden
Demographic factors in the Chinese healthcare system

Age profile
Modernization
Affordability

Economic landscape

Healthcare spending
Key events in China’s economic landscape

The increased importance of domestic consumption
China’s economic growth in 2009 could be much worse than expected

Measures that could mitigate the economic downturn in China

Environmental landscape

Chapter 3 The Chinese healthcare system

Summary
Introduction
Recent developments in the healthcare sector

All villages in China to have a medical clinic in the next three years
The Chinese government will deal with rural medical staff shortages
Amended healthcare reforms will strengthen the healthcare system in urban and rural areas
An essential drugs list (EDL) to curb the rising drug prices in China
The Chinese MOH takes responsibility for food safety monitoring

Chinese drug regulatory system

Intellectual property protection
Pricing and reimbursement
The Chinese drug approval system
Drug advertising in China
The drug distribution system

The future of Chinese healthcare reforms
Chinese biotech developments

Improving scientific base
Chinese biosimilar market
Major biosimilars in China

Chapter 4 Chinese hospital market analysis

Summary
Introduction
The Chinese hospital pharmaceutical market
Traditional Chinese medicines (TCMs)
The domestic Chinese pharmaceutical market
Multinationals versus domestic companies
Investment in China based R&D
Therapy area analysis
Therapy area sales forecast
Leading products dynamics
Leading products sales forecast

Chapter 5 Key players in the Chinese hospital pharmaceutical market

Summary
Introduction
Competitive positioning of the top pharmaceutical players in hospital settings
Detailed analysis of key players in the Chinese hospital pharmaceutical market

Pfizer

Overview
Sales focus by leading therapeutic area
Marketed product portfolio
Pfizer’s pipeline focus
Strategic growth analysis

AstraZeneca

Overview
Sales focus by leading therapeutic area
Marketed product portfolio
AstraZeneca’s pipeline focus
Strategic growth analysis

Bayer

Overview
Sales focus by leading therapeutic area
Marketed product portfolio
Bayer’s pipeline focus
Strategic growth analysis

Sanofi-Aventis

Overview
Sales focus by leading therapeutic area
Marketed product portfolio
Sanofi-Aventis’s pipeline focus
Strategic growth analysis

Roche

Overview
Sales focus by leading therapeutic area
Marketed product portfolio
Roche’s pipeline focus
Strategic growth analysis

Novartis

Overview
Sales focus by leading therapeutic area
Marketed product portfolio
Novartis’s pipeline focus
Strategic growth analysis

Chapter 6 Appendix

Anatomical Therapeutic Classification (ATC)

A: Alimentary tract and metabolism
B: Blood and blood-forming organs
C: Cardiovascular system
D: Dermatologicals
G: Genito-urinary system and sex hormones
H: Systemic hormonal preparations
J: General anti-infectives systemic
K: Hospital solutions
L: Antineoplastic and immunomodulating agents
M: Musculo-skeletal system
N: Nervous system
P: Parasitology
R: Respiratory system
S: Sensory organs
T: Diagnostic agents
V: Various

Glossary
Index

List of Figures
Figure 2.1: Population demographics in China, 2008
Figure 2.2: Comparison of healthcare expenditures across seven emerging pharmaceutical markets
Figure 3.3: Drug approval process in China
Figure 3.4: Drug distribution channels in China
Figure 4.5: Top 10 sub-therapy area sales in the Chinese hospital pharmaceutical market, 2008
Figure 5.6: Pfizer’s Chinese market sales by therapy area, 2008
Figure 5.7: AstraZeneca’s Chinese market sales by therapy area, 2008
Figure 5.8: Bayer’s Chinese market sales by therapy area, 2008
Figure 5.9: Sanofi-Aventis’s Chinese market sales by therapy area, 2008
Figure 5.10: Roche’s Chinese market sales by therapy area, 2008
Figure 5.11: Novartis’s Chinese market sales by therapy area, 2008

List of Tables
Table 2.1: Forecast epidemiology of risk factors/common disorders in China, 2008-14
Table 3.2: Major biosimilars in China
Table 3.3: Patent expirations of top selling innovator biologics
Table 4.4: Chinese hospital pharmaceutical market by therapy area sales growth, 2008
Table 4.5: Chinese hospital pharmaceutical market sales forecast by ATC code, 2008-14
Table 4.6: Leading products in the Chinese hospital pharmaceutical market, 2008
Table 4.7: Leading products sales forecast, 2008.14
Table 5.8: Leading players in the Chinese hospital pharmaceutical market, 2008
Table 5.9: Pfizer’s leading products in the Chinese hospital pharmaceutical market, 2008
Table 5.10: AstraZeneca’s leading products in the Chinese hospital pharmaceutical market, 2008
Table 5.11: Bayer’s leading products in the Chinese hospital pharmaceutical market, 2008
Table 5.12: Sanofi-Aventis’s leading products in the Chinese hospital pharmaceutical market, 2008
Table 5.13: Roche’s leading products in the Chinese hospital pharmaceutical market, 2008
Table 5.14: Novartis’s leading products in the Chinese hospital pharmaceutical market, 2008